Compliance Information
ESMO Asia 2024 is organised by the European Society for Medical Oncology (based in Lugano, Switzerland). The congress is provided to international HCPs with a majority from Asia, in accordance with the international Industry Code of Practices and/or local approval in each country.
EFPIA accreditation
The EFPIA accreditation submission has been taken care by ESMO, as ESMO is the content owner and organiser of the ESMO Asia Congresses. Please do not submit any accreditation request to EFPIA on behalf of ESMO. ESMO Asia 2024 Submission has been assigned with the reference number EMT-24-00485 and the current status of the event is compliant. You can see and follow the submission status here.
Should you have any queries or doubts on the EFPIA accreditation for ESMO Asia Congresses do not hesitate to contact asiacongress@esmo.org.
On-site regulation
Participants fully registered to the congress, visitors wearing the visitors’ badge, exhibitors wearing the exhibitor badge and agencies wearing the Industry Satellite badge will have access to the satellite symposia sessions, at the discretion of the sponsoring company. For ESMO Asia 2024, different badge coloured stripes will be used in order to allow identification of delegates as prescribers or non-prescribers. This decision has been taken to comply with prescription-only medicines promotional legislation, as far as applicable. (i) Delegates attending the Congress will be responsible when deciding which parts or areas of the congress they access, and (ii) By previously identifying their profile, pharmaceutical companies will be responsible when deciding how they engage or interact with participants, according to applicable laws and Codes of Practice.